Sex steroids and insulin resistance

Clinical Science

Volumn 102, Issue 2, 2002, Pages 151-166

  Livingstone, Callum ^a   Collison, Mary ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Androgens; Glucose transporters; Insulin resistance; Oestrogens; Polycystic ovarian syndrome; Type II diabetes

Indexed keywords

ANDROGEN; GLUCOSE; GONADORELIN; INSULIN; LIPOPROTEIN LIPASE; METFORMIN; PRASTERONE; SEX HORMONE; THIAZOLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONGENITAL ADRENAL HYPERPLASIA; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR BIOLOGY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES MELLITUS, TYPE 2; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RATS; TESTOSTERONE;

EID: 0036185539     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20010197     Document Type: Review

References (136)

1. Insulin sensitivity in women with polycystic ovary syndrome: Relationship to hyperandrogenaemia
2. Prevalence and predictors of risk for type-2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
3. Decreased testosterone and DHEAS concentrations are associated with increased insulin and glucose concentrations in non-diabetic men
4. Some important endocrine organs and hormones
5. What is insulin resistance?
6. Glucose clamp technique: A method for quantifying insulin secretion and resistance
7. Glucose turnover. A key to understanding the pathogenesis of diabetes
8. Insulin resistance - Mechanisms, syndromes and implications
9. The insulin signaling pathway
10. Tyrosine-specific protein kinase activity is associated with the insulin receptor
11. The IRS signalling system: A network of docking proteins that mediate insulin action
12. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling
13. A retroviral oncogene akt encoding a serine-threonine kinase containing an SH2-like region
14. Mechanism of activation of protein kinase B by insulin and IGF-1
15. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport
16. The glucose transporter family
17. Trafficking, targeting and translocation of the insulin-regulatable transporter GLUT4
18. Insulin resistance, hypertension and GLUT4
19. Puberty reduces insulin sensitivity
20. Insulin resistance of puberty: A defect restricted to peripheral glucose metabolism
21. The roles of insulin sensitivity, IGF-1 and IGF-BP-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche
22. Alterations of maternal metabolism in normal and diabetic pregnancies: Difference in insulin dependent, non-insulin dependent and gestational diabetes
23. Induction of insulin resistance by androgens and estrogens
24. Insulin resistance in polycystic ovary syndrome
25. The effect of anabolic steroids on blood sugar and plasma insulin levels in man
26. Effects of methyltestosterone on insulin secretion and sensitivity in women
27. Glucose intolerance and insulin resistance in aplastic anaemia treated with oxymetholone
28. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids
29. Insulin resistance, secretion and metabolism in users of oral contraceptives
30. Amelioration of insulin resistance in diabetes mellitus with DHEA
31. Insulin resistance, body fat distribution and sex hormones in men
32. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men
33. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitus
34. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome
35. Polycystic ovarian syndrome, hyperandrogenism and insulin resistance
36. The long term consequences of polycystic ovary syndrome
37. Hyperandrogenicity in women - A prediabetic condition?
38. Clinical signs of androgen excess risk factors for coronary artery disease
39. Searching for the polycystic ovary syndrome genes
40. Phenotype and genotype in polycystic ovary syndrome
41. Polycystic ovary syndrome and insulin resistance: Thrifty genes struggling with over-feeding and sedentary lifestyle?
42. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinaemia
43. Insulin resistance in non-obese patients with polycystic ovarian disease
44. The association of girth measurements with disease in 32,856 women
45. Health implications of obesity
46. On the paradox of insulin-induced hyperandrogenism in insulin resistant states
47. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome
48. Serine phosphorylation of human P450c17 increases 17,20 lyase activity: Implications for adrenarche and the polycystic ovary syndrome
49. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity
50. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
51. Suppression of serum insulin by diazoxide reduces serum testosterone level in obese women with polycystic ovary syndrome
52. Inhibin, activin and follistatin: Potential roles in ovarian physiology
53. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin
54. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein-1 in the polycystic ovary syndrome
55. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 in the pathogenesis of polycystic ovary syndrome
56. Polycystic ovaries in non-obese and obese patients: Possible pathophysiological mechanism based on new interpretation of facts and findings
57. Puberty and polycystic ovarian syndrome: The insulin/insulin-like growth factor I hypothesis
58. Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome
59. Development of insulin resistance in 3T3-L1 adipocytes
60. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency
61. Persistent insulin resistance after normalization of androgen levels in a woman with congenital adrenal hyperplasia. A case report
62. Insulin receptors in circulating erythrocytes and monocytes from women on oral contraceptives or pregnant women near term
63. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin resistant state distinct from the type A and B syndromes
64. Evidence for insulin resistance in non-obese patients with polycystic ovarian disease
65. Evidence for distinctive and intrinsic defects in insulin action in the polycystic ovarian syndrome
66. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
67. Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT4 glucose transporters in adipocytes
68. Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovarian syndrome
69. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome (PCOS)
70. The insulin receptor and its substrate: Molecular determinants of early events in insulin action
71. The effects of oestrogen and progesterone on insulin sensitivity in female rats
72. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment
73. Effect of ovarian hormones on glucose metabolism in mouse soleus muscle
74. Effect of estradiol on tissue glycogen metabolism in exercised oophorectomised rats
75. Expression of GLUT4 mRNA in adipose tissue and skeletal muscle in ovariectomised rats treated with sex steroid hormones
76. GLUT4 mRNA abundance in the adipose tissue and skeletal tissue of ovariectomised rats treated with 17 beta-estradiol or progesterone
77. Regulation of glycogen synthesis in human muscle cells
78. Effects of testosterone on muscle insulin sensitivity and morphology in female rats
79. Effects of short term testosterone exposure on insulin sensitivity of muscles in female rats
80. The effects of testosterone on insulin sensitivity in male rats
81. Differential response of rat skeletal muscle glycogen metabolism to testosterone and oestradiol
82. Induction of insulin dependent diabetes by streptozotocin: Inhibition by estrogens and potentiation by androgens
83. Regulation of glucose transporters by estradiol in the immature rat uterus
84. 17 Beta-estradiol modulation of glucose transporter 1 expression in blood brain barrier
85. Sex hormones induce insulin resistance in 3T3-L1 adipocytes by reducing cellular content of IRS proteins
86. Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance
87. Insulin sensitivity and fertility
88. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome
89. Effects of estrogen on skeletal myoblast growth
90. The role of DHEA in diabetes mellitus
91. Insulin resistance and advancing age: What role for DHEA?
92. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging
93. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females
94. Obesity and metabolic complications: Contribution of DHEA and other steroid hormones
95. Acute hyperinsulinemia, androgen homeostasis and insulin sensitivity in healthy men
96. DHEA and body fat
97. DHEA in morbidly obese adolescents: Effects on weight, body composition, lipids and insulin resistance
98. Enhanced post-receptor insulin effects in women following DHEA infusion
99. DHEA and DHEAS as therapeutic options in menopause
100. DHEA treatment reduces fat accumulation and protects against insulin resistance
101. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet
102. DHEA ameliorates the insulin sensitivity in older rats
103. DHEA decreases serum TNF-α and restores insulin sensitivity: Independent effect from secondary weight reduction in genetically obese Zucker fatty rats
104. DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase
105. The role of atypical and conventional PKC in DHEA-induced glucose uptake and dexamethasone-induced insulin resistance
106. The endothelium as a metabolic and endocrine organ: Its relation with insulin resistance
107. The association between insulin resistance and endotheliopathy
108. Insulin and the vasculature
109. Adverse endothelial function and the insulin resistance syndrome
110. Oestrogen and vascular disease
111. Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women
112. Polycystic ovary syndrome is associated with endothelial dysfunction
113. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome
114. Evidence for association between polycystic ovary syndrome and premature carotid arteriosclerosis in middle aged women
115. Metformin corrects vascular insulin resistance in hypertension
116. Regulation of the synthesis, processing and translocation of lipoprotein lipase
117. Dissociation between plasma triglyceride concentration and tissue lipoprotein lipase deficiency in insulin deficient rats
118. Estrogen treatment and gonadal function in the regulation of lipoprotein lipase
119. Effect of estrogen on lipoprotein lipase activity and cytoplasmic progestine binding sites in lean and obese Zucker rats
120. Effects of estradiol on lipoprotein lipase activity and lipid availability in exercised male rats
121. Relationship between lipoprotein lipase activity and plasma steroid level in obese women
122. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males
123. Impaired insulin action in subcutaneous adipocytes from women with visceral obesity
124. Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity
125. Insulin-lowering drugs in polycystic ovary syndrome
126. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia and systolic blood pressure while facilitating normal menses and pregnancy
127. Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin
128. Metformin and intervention in polycystic ovary syndrome
129. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides
130. Thiazolidinediones - Tools for the research of metabolic syndrome X
131. A thiazolidinedione improves in vivo insulin action on skeletal muscle glycogen synthase in insulin resistant monkeys
132. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
133. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome
134. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3 beta-hydroxysteroid dehydrogenase
135. Insulin resistance improves in hyperandrogenic women treated with Lupron
136. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in PCOS